Biogen CEO Stepping Down
Biogen Inc (NASDAQ:BIIB)'s Chief Executive Officer Michel Vounatsos is stepping down after the unwanted incident takes place.
Biogen is grappling with Medicare proscribing protection for its Alzheimer's drug Aduhelm to patients in medical trials.
Biogen grappling with Medicare
Biogen CEO Vounatsos will Continue till
Vounatsos, who will proceed in his position till his successor is appointed, was named because the CEO in 2016
Biogen developed and launched a number of flagship medication together with spinal muscular atrophy drug Spinraza & Aduhelm.
Biogen- Drugs developed by the Company
Biogen to limit Alzheimer Drug
Biogen considerably eliminating commercial infrastructure associated to the Alzheimer's drug.
Biogen was betting on Aduhelm, the primary new remedy for the memory-robbing illness in almost 20 years
Biogen betting on Aduhelm
Biogen testing 2nd Alzheimer Drug
Biogen is now relying on its second Alzheimer's drug lecanemab, which like Aduhelm developed with Japanese Firm
Biogen shares are down 13% from the beginning of the year and are trading at $207.32 , down-from-52-week-high.
Biogen Company Shares
Biogen CEO Stepping Down- Swipe Up!!!
Swipe Up for More WebStories related to Technology, Finance, Gaming, Gadgets Review, & Other Trending News.